Biopharma
ByWill Axsome Therapeutics’ FDA Priority Review of AXS-05 Address a Long-Standing Gap in Alzheimer’s Disease Agitation Treatment?
New York – December 31, 2025 — Axsome Therapeutics has reached a major regulatory milestone after the U.S.…
Did Ophthalmic Therapy Approvals in 2025 Redefine Vision Care—and Set the Stage for Accelerated Innovation in 2026?
Global – December 2025 — The ophthalmology therapeutic area entered a renewed phase of innovation in 2025, driven…
Did Metabolic Therapy Approvals in 2025 Reset the Standard of Care—and Ignite a New Growth Cycle in 2026?
Global – December 2025 — The metabolic therapeutic area emerged as one of the most transformative forces in…
Did Renal Therapy Approvals in 2025 Redefine Kidney Disease Management—and Set the Stage for Breakthroughs in 2026?
Global – December 2025 — The renal therapeutic area emerged as a renewed focus of innovation in 2025,…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS and Janux Strike $850 Million T-Cell Engager Deal
22 January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics,…
Can Global Partnerships Future-Proof Epidemic Preparedness? SK bioscience, Merck (MSD), and Hilleman Unite to Strengthen Ebola Vaccine Supply
23 January 2026 Executive Summary A global vaccine partnership has been established between SK bioscience, MSD (Merck &…
